Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2012
06/07/2012WO2012075048A2 Hybrid cyclic libraries and screens thereof
06/07/2012WO2012075026A1 Methods of treating obesity using an effective dose of a metap-2 inhibitor
06/07/2012WO2012075020A1 Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
06/07/2012WO2012075015A2 Oral metronidazole pharmaceutical compositions
06/07/2012WO2012074999A1 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
06/07/2012WO2012074988A1 Rotigotine ionic liquid
06/07/2012WO2012074980A2 Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
06/07/2012WO2012074968A1 Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
06/07/2012WO2012074960A2 Fty720-derived anticancer agents
06/07/2012WO2012074951A1 Macrocyclic kinase inhibitors
06/07/2012WO2012074930A2 Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
06/07/2012WO2012074926A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074921A1 Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators
06/07/2012WO2012074912A1 Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
06/07/2012WO2012074898A1 Novel alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074869A1 Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
06/07/2012WO2012074830A2 Modified release tranexamic acid formulation
06/07/2012WO2012074799A1 Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
06/07/2012WO2012074788A1 Methods for treating diseases of the retina
06/07/2012WO2012074785A1 Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
06/07/2012WO2012074782A1 Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074780A1 Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074774A1 Methods for the treatment of fibromyalgia and chronic fatigue syndrome
06/07/2012WO2012074769A1 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds
06/07/2012WO2012074761A1 Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
06/07/2012WO2012074757A1 Alaninyl maytansinol antibody conjugates
06/07/2012WO2012074754A1 Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
06/07/2012WO2012074732A1 Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074730A1 Oxadiazole derivatives as sphingosine 1-phosphate (s1p)receptor modulators
06/07/2012WO2012074722A1 Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074719A1 Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074718A1 Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074703A1 Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
06/07/2012WO2012074676A2 Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto
06/07/2012WO2012074660A1 Electrokinetic device for capturing assayable agents in a dielectric fluid
06/07/2012WO2012074561A2 Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
06/07/2012WO2012074547A2 STEROID COMPOUNDS AS RORγt MODULATORS AND USES THEREOF
06/07/2012WO2012074490A1 Control of bacterial growth
06/07/2012WO2012074469A1 New ikach blockers
06/07/2012WO2012074401A1 Prevention or treatment of overweight and obesity in type 2 diabetic patients
06/07/2012WO2012074375A1 Prevention or treatment of overweight and obesity in type 2 diabetic patients
06/07/2012WO2012074285A2 Agent for stabilizing peptides or proteins
06/07/2012WO2012074249A2 Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
06/07/2012WO2012074244A2 Injectable liquid composition or injectable dried powder containing revaprazan or its salt
06/07/2012WO2012074243A2 Injectable liquid composition containing revaprazan or its salt
06/07/2012WO2012074237A2 Liquid medicine composition including dorzolamide and brimonidine for ophthalmology
06/07/2012WO2012074231A2 Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
06/07/2012WO2012074187A1 Pharmaceutical composition for preventing or treating autophagy-related diseases, angiogenic diseases or melanin-related diseases
06/07/2012WO2012074184A1 Pharmaceutical composition for preventing or treating obesity comprising sphingosine-1-phosphate or a pharmaceutically acceptable salt thereof as an active ingredient
06/07/2012WO2012074180A1 Novel tetraazacyclododecan-tetraone derivative or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same for preventing or treating cancer
06/07/2012WO2012074137A1 Method for evaluating drug sensitivity by voltage-dependent calcium channel genetic analysis
06/07/2012WO2012074126A1 Bicyclic compound
06/07/2012WO2012074120A1 Lissencephaly therapeutic agent
06/07/2012WO2012074116A1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH α CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM Vα-Jα, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
06/07/2012WO2012074110A1 Orally disintegrating tablet
06/07/2012WO2012074085A1 Marker for determination of sensitivity to triplet combination anti-cancer agent
06/07/2012WO2012074069A1 Novel compound and medical use thereof
06/07/2012WO2012074067A1 Pyrazole compound having therapeutic effect on multiple myeloma
06/07/2012WO2012074040A1 Buguanide derivative compound
06/07/2012WO2012074038A1 Modified single-strand polynucleotide
06/07/2012WO2012073995A1 Heteroaromatic ring compound and pest control application thereof
06/07/2012WO2012073991A1 Pyrrole derivative and process for production thereof
06/07/2012WO2012073965A1 Insulin secretagogue
06/07/2012WO2012073891A1 Transfusion preparation
06/07/2012WO2012073856A1 Oil-in-water emulsion composition containing difluprednate and tobramycin
06/07/2012WO2012073601A1 Inhibitor of attachment of periodontal-disease-inducing bacterium onto surfaces of teeth, oral biofilm formation inhibitor, and composition for oral applications
06/07/2012WO2012073375A1 Novel compound, and kinesin spindle protein inhibitor and application thereof
06/07/2012WO2012073256A1 Salts of rosuvastatin
06/07/2012WO2012073237A1 Uridine di- or tri-phosphate derivatives and uses thereof
06/07/2012WO2012073217A1 Process for the preparation of morpholinyl anthracycline derivatives
06/07/2012WO2012073214A2 New heptose derivatives and biological applications thereof
06/07/2012WO2012073191A1 Topical compositions for preserving or restoring the integrity of mucosae
06/07/2012WO2012073188A1 Chemoembolization composition comprising anti-angiogenic agents
06/07/2012WO2012073184A1 Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases
06/07/2012WO2012073146A1 Kat ii inhibitors
06/07/2012WO2012073143A1 Kat ii inhibitors
06/07/2012WO2012073138A1 Monobactams
06/07/2012WO2012073077A1 Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
06/07/2012WO2012073055A1 Method for the preparation of high-purity pharmaceutical intermediates
06/07/2012WO2012073047A2 Compositions and methods
06/07/2012WO2012073025A1 Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
06/07/2012WO2012073020A1 Glucan compositions
06/07/2012WO2012073019A1 Glucan gels
06/07/2012WO2012073018A1 Glucans
06/07/2012WO2012073017A1 Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
06/07/2012WO2012072977A2 Compound formulations
06/07/2012WO2012072824A1 Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
06/07/2012WO2012072820A1 Methods and pharmaceutical compositions for the treatment of heart failure
06/07/2012WO2012072791A2 2-(1-phenyl-4,5,6,7-tetrahydro-1h-indazol-4-yl)ethylamine derivatives useful as sigma receptor inhibitors
06/07/2012WO2012072782A1 Use of sigma ligands in bone cancer pain
06/07/2012WO2012072781A1 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
06/07/2012WO2012072727A1 Crystalline modification of n-(3,5-dichloropyridin-4-yl)-[1-(4 -fluorobenzyl)-7-azaindol-3-yl)]glyoxylic acid amide as inhibitor of pde4
06/07/2012WO2012072709A1 Use of a food composition in the treatment and/or prevention of neuropathic pain induced by an anticancer agent
06/07/2012WO2012072692A2 Use of cytokine-releasing, biodegradable particles in hyaluronic acid for the treatment of cartilage defects, in particular of osteoarthrosis
06/07/2012WO2012072691A1 Indanyloxydihydrobenzofuranylacetic acids
06/07/2012WO2012072689A1 Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
06/07/2012WO2012072665A1 Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
06/07/2012WO2012072655A1 New treatments of hepatitis c virus infection
06/07/2012WO2012072650A1 Transdermal therapeutic system (tts) comprising rotigotine
06/07/2012WO2012072620A1 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1h-benzo[e][1,4]diazepin-2(3h)-one and other benzodiazepine derivatives
1 ... 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 ... 7860